Analyst Price Target is $8.00
▲ +708.00% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Connect Biopharma in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 708.00% upside from the last price of $0.99.
Current Consensus is
Buy
The current consensus among 1 polled investment analysts is to buy stock in Connect Biopharma. This rating has held steady since April 2023, when it changed from a Moderate Buy consensus rating.
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
Read More
